Cargando…

Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy

BACKGROUND: The overall treatment time of stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer is usually 3 to over 10 days. If it is longer than 7 days, tumor volume expansion during SBRT may jeopardize the target dose coverage. In this study, volume change of stage I NSCLC during S...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatekawa, Kotoha, Iwata, Hiromitsu, Kawaguchi, Takatsune, Ishikura, Satoshi, Baba, Fumiya, Otsuka, Shinya, Miyakawa, Akifumi, Iwana, Maho, Shibamoto, Yuta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904205/
https://www.ncbi.nlm.nih.gov/pubmed/24393430
http://dx.doi.org/10.1186/1748-717X-9-8
_version_ 1782301199393882112
author Tatekawa, Kotoha
Iwata, Hiromitsu
Kawaguchi, Takatsune
Ishikura, Satoshi
Baba, Fumiya
Otsuka, Shinya
Miyakawa, Akifumi
Iwana, Maho
Shibamoto, Yuta
author_facet Tatekawa, Kotoha
Iwata, Hiromitsu
Kawaguchi, Takatsune
Ishikura, Satoshi
Baba, Fumiya
Otsuka, Shinya
Miyakawa, Akifumi
Iwana, Maho
Shibamoto, Yuta
author_sort Tatekawa, Kotoha
collection PubMed
description BACKGROUND: The overall treatment time of stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer is usually 3 to over 10 days. If it is longer than 7 days, tumor volume expansion during SBRT may jeopardize the target dose coverage. In this study, volume change of stage I NSCLC during SBRT was investigated. METHODS: Fifty patients undergoing 4-fraction SBRT with a total dose of 48 Gy (n = 36) or 52 Gy (n = 14) were analyzed. CT was taken for registration at the first and third SBRT sessions with an interval of 7 days in all patients. Patient age was 29–87 years (median, 77), and 39 were men. Histology was adenocarcinoma in 28, squamous cell carcinoma in 17, and others in 5. According to the UICC 7th classification, T-stage was T1a in 9 patients, T1b in 27, and T2a in 14. Tumor volumes on the first and 8th days were determined on CT images taken during the exhalation phase, by importing the data into the Dr. View/LINAX image analysis system. After determining the optimal threshold for distinguishing tumor from pulmonary parenchyma, the region above -250 HU was automatically extracted and the tumor volumes were calculated. RESULTS: The median tumor volume was 7.3 ml (range, 0.5-35.7) on day 1 and 7.5 ml (range, 0.5-35.7) on day 8. Volume increase of over 10% was observed in 16 cases (32%); increases by >10 to ≤20%, >20 to ≤30%, and >30% were observed in 9, 5, and 2 cases, respectively. The increase in the estimated tumor diameter was over 2 mm in 3 cases and 1–2 mm in 6. A decrease of 10% or more was seen in 3 cases. Among the 16 tumors showing a volume increase of over 10%, T-stage was T1a in 2 patients, T1b in 9, and T2a in 5. Histology was adenocarcinoma in 10 patients, squamous cell carcinoma in 5, and others in 1. CONCLUSIONS: Volume expansion >10% was observed in 32% of the tumors during the first week of SBRT, possibly due to edema or sustained tumor progression. When planning SBRT, this phenomenon should be taken into account.
format Online
Article
Text
id pubmed-3904205
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39042052014-01-29 Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy Tatekawa, Kotoha Iwata, Hiromitsu Kawaguchi, Takatsune Ishikura, Satoshi Baba, Fumiya Otsuka, Shinya Miyakawa, Akifumi Iwana, Maho Shibamoto, Yuta Radiat Oncol Research BACKGROUND: The overall treatment time of stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer is usually 3 to over 10 days. If it is longer than 7 days, tumor volume expansion during SBRT may jeopardize the target dose coverage. In this study, volume change of stage I NSCLC during SBRT was investigated. METHODS: Fifty patients undergoing 4-fraction SBRT with a total dose of 48 Gy (n = 36) or 52 Gy (n = 14) were analyzed. CT was taken for registration at the first and third SBRT sessions with an interval of 7 days in all patients. Patient age was 29–87 years (median, 77), and 39 were men. Histology was adenocarcinoma in 28, squamous cell carcinoma in 17, and others in 5. According to the UICC 7th classification, T-stage was T1a in 9 patients, T1b in 27, and T2a in 14. Tumor volumes on the first and 8th days were determined on CT images taken during the exhalation phase, by importing the data into the Dr. View/LINAX image analysis system. After determining the optimal threshold for distinguishing tumor from pulmonary parenchyma, the region above -250 HU was automatically extracted and the tumor volumes were calculated. RESULTS: The median tumor volume was 7.3 ml (range, 0.5-35.7) on day 1 and 7.5 ml (range, 0.5-35.7) on day 8. Volume increase of over 10% was observed in 16 cases (32%); increases by >10 to ≤20%, >20 to ≤30%, and >30% were observed in 9, 5, and 2 cases, respectively. The increase in the estimated tumor diameter was over 2 mm in 3 cases and 1–2 mm in 6. A decrease of 10% or more was seen in 3 cases. Among the 16 tumors showing a volume increase of over 10%, T-stage was T1a in 2 patients, T1b in 9, and T2a in 5. Histology was adenocarcinoma in 10 patients, squamous cell carcinoma in 5, and others in 1. CONCLUSIONS: Volume expansion >10% was observed in 32% of the tumors during the first week of SBRT, possibly due to edema or sustained tumor progression. When planning SBRT, this phenomenon should be taken into account. BioMed Central 2014-01-07 /pmc/articles/PMC3904205/ /pubmed/24393430 http://dx.doi.org/10.1186/1748-717X-9-8 Text en Copyright © 2014 Tatekawa et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tatekawa, Kotoha
Iwata, Hiromitsu
Kawaguchi, Takatsune
Ishikura, Satoshi
Baba, Fumiya
Otsuka, Shinya
Miyakawa, Akifumi
Iwana, Maho
Shibamoto, Yuta
Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy
title Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy
title_full Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy
title_fullStr Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy
title_full_unstemmed Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy
title_short Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy
title_sort changes in volume of stage i non-small-cell lung cancer during stereotactic body radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904205/
https://www.ncbi.nlm.nih.gov/pubmed/24393430
http://dx.doi.org/10.1186/1748-717X-9-8
work_keys_str_mv AT tatekawakotoha changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy
AT iwatahiromitsu changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy
AT kawaguchitakatsune changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy
AT ishikurasatoshi changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy
AT babafumiya changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy
AT otsukashinya changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy
AT miyakawaakifumi changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy
AT iwanamaho changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy
AT shibamotoyuta changesinvolumeofstageinonsmallcelllungcancerduringstereotacticbodyradiotherapy